WO1987000034A2 - Artificial bezoar - Google Patents

Artificial bezoar Download PDF

Info

Publication number
WO1987000034A2
WO1987000034A2 PCT/GB1986/000392 GB8600392W WO8700034A2 WO 1987000034 A2 WO1987000034 A2 WO 1987000034A2 GB 8600392 W GB8600392 W GB 8600392W WO 8700034 A2 WO8700034 A2 WO 8700034A2
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
overtube
stomach
supply line
valve
Prior art date
Application number
PCT/GB1986/000392
Other languages
French (fr)
Inventor
Thomas Vincent Taylor
Original Assignee
Thomas Vincent Taylor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Vincent Taylor filed Critical Thomas Vincent Taylor
Publication of WO1987000034A2 publication Critical patent/WO1987000034A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013—Implantable devices or invasive measures
    • A61F5/003—Implantable devices or invasive measures inflatable

Definitions

  • the present invention relates to artificial bezoars and to apparatus for treating obesity which includes an artificial bezoar.
  • a second problem is how to achieve oral insertion without damaging oesophageal tissue, and yet another problem is to achieve reliable inflation of a balloon after it has been introduced into the stomach cavity.
  • EP-0137878-A discloses apparatus which includes a stomach tube which contains an uninflated stomach balloon at a leading end of the stomach tube. This one end of the stomach tube is slit to the end of the tube, and the slit
  • apparatus for treating obesity in a patient comprising a valved balloon for placement in the stomach of the patient and a fluid supply line having a far end detachably connected to the valve and l& a near end for connection externally of the patient to a fluid supply means for inflation of the balloon within the stomach, the supply line and the balloon prior to its . inflation being accommodated within an overtube by which the balloon may be introduced orally into the stomach, the
  • 20uninflated balloon being housed adjacent a leading end of the overtube, characterised in that the leading end of. the overtube is closed and has a smoothly convex shape, and in that the cylindrical wall of the overtube adjacent said closed leading end includes an elongate fully-bounded
  • a flexible tube 30of a length in a range from 60 to 70 cms and a diameter in the range of from 1 to 1.5 cms similar to the tubes which are currently employed for gastric aspiration.
  • the tip of the overtube is smooth and the inflating balloon exits through a lengthwise sideways-facing slit-, so that the 35leading end of the overtube is easily introduced into the stomach and removed from it.
  • a standard Luer fitting for convenient attachment to a fluid source, which may be, for example, a syringe or an infusion line.
  • a fluid source which may be, for example, a syringe or an infusion line.
  • the leading i.e. distal end is tapered for insertion into a correspondingly shaped female element of the valve of the balloon for the purpose of inflation, and subsequent detachment by traction to leave the balloon free-floating in the stomach.
  • the balloon is of pear (piriform) or oval (ellipsoidal) shape and is of elastomeric material .
  • it is inflated through a self-sealing valve located at a narrow end of the balloon.
  • a balloon of ellipsoidal or piriform shape complies more easily with the natural pear shape of the human stomach than does a spherical balloon, and without producing undue dilation of the central stomach. Such dilation could produce abdominal discomfort around the widest .parts of the balloon and impair the process of gastric emptying.
  • the longitudinal axis of the balloon will tend to align with the longitudinal axis of the stomach, and the balloon will be .Tiore likely to occupy space in the more proximal stomach where the satiety centre is thought to lie.
  • a balloon of the preferred shape will furthermore leave less of the reservoir capacity of the stomach available for food storage and will have a greater flexibility for increased capacity without producing undue gastric distortion, stretching tension or mucosal damage.
  • the balloon should be adapted to contain about 500 millilitres of liquid under inflation in normal use, but preferably it should be able when required to accommodate liquid up to an amount of 1 litre or more.
  • the wall thickness should be as small as .possible for passage along the oesophagus whilst deflated but large enough to withstand the long-term, potentially damaging, effects of intragastric acid, food products and pressure effects of the vigorously contracting stomach.
  • the chosen wall thickness is the optimum compromise between these opposed requi rements .
  • the balloon valve should be competent and continent against fluid leakage over a relatively long period of time, that is, a period of months, say six months.
  • it is constructed of the same material as the balloon for ease of manufacture and it should add to the weight of the balloon as little as possible.
  • an artificial bezoar being a capsule adapted to be swallowed or otherwise delivered orally to the stomach the capsule comprising a resilient balloon arranged in a compact, deflated disposition and containing a substance which is capable of undergoing a change of volume of at least two decimal orders of magnitude to inflate the balloon in the stomach.
  • the substance is capable of undergoing such a change of volume is for it to undergo a chemical reaction which results in the evolution of gas.
  • the gas should be one which does not harm the human body.
  • Carbon dioxide is considered acceptable.
  • the capsule might contain a substance such as sodium bicarbonate which reacts with hydrochloric acid to generate gasesous carbon dioxide.
  • the acid could be introduced into the capsule by injection with a needle through a self-sealing wall area of the capsule, and the capsule swallowed immediately thereafter so that inflation of the balloon takes place in the stomach. Tube delivery to the stomach, instead of swallowing, would avoid possible blockage of the oesophagus as a result of premature balloon inflation.
  • the balloon from a material which is a semi -per eabl e membrane .
  • a material which is a semi -per eabl e membrane and to enclose within the balloon a small amount of a substance which has the capacity to absorb, in large quantity, the water or gastric fluid which passes inwardly into the balloon through the semi -permeabl e membrane wall .
  • certain cellulose materials have the necessary properties.
  • the balloon are packaged in a tight and compact disposition within a capsule which is adapted to be swallowed and is formed from a material which dissolves in the stomach to allow contact of the gastric fluids with the semi -permeabl e membrane balloon.
  • Figure 1 is a perspective view of a first embodiment of the invention
  • Figure 2 is a scrap section along the longitudinal axis of the valve of the balloon of Figure 1;
  • Figure 3 is a side view, partly in .section, of a capsule which is a second embodiment of the invention.
  • Figure 4 is view like Figure 3, of a third embodiment .
  • a balloon 10 of silicone rubber has a valve 11 which accommodates the distal end 12 of a liquid supply line 13 which extends the full length of an overtube 14 to a liquid supply syringe 15.
  • a liquid supply line 13 which extends the full length of an overtube 14 to a liquid supply syringe 15.
  • liquid may be delivered down the supply line to the balloon 10 to inflate it and cause it to exit the overtube 14 through an elongate, fully bounded aperture 17 in the cylindrical wall of the overtube 14 adjacent its distal end 16.
  • Figure 2 shows the construction of the valve 11.
  • a hollow stem 20 bonded to the wall of the balloon 10 has a closed end 21 but an aperture 22 in its cylindrical wall 23.
  • a sealing sleeve 24 overlies the aperture 22 and allows liquid to flow from inside the stem 20 to inside the cavity of the balloon 10 but not in the opposite direction.
  • the sleeve 24 could be a skirt around the stem 20 or a flap over the aperture 22.
  • valve 11 can be so designed that manual squeezing of it will allow fluid to escape through the valve.
  • the distal end 12 of the supply line 13 is a firm friction fit in the stem 20.
  • tension on the supply line 13 will bring the balloon up against either the overtube or the oesophageal sphincter, and further pulling of the supply line will draw the distal end thereof out of the hollow stem 20 of the valve 11 and allow the balloon to float freely within the stomach, if the supply line is made of resilient material , tension on it will tend to reduce its diameter. This effect should assist its disengagement from the stem 20 of the valve 13.
  • the capsule 30 of Figure 3 contains a tightly-packed balloon 31 with a neck 32 bonded to an open end 33 of a short length of tube 34.
  • the other end 35 of the tube 34 is closed by a self-sealing elasto eric plug 36 of a material which resists chemical attack by stomach acids but allows passage of a syringe needle and closes up after passage of the needle.
  • 500 ml of CO2 is generated by injecting 1 ml of N/10 Hydrochloric acid into 1 g of sodium bicarbonate. Inflation of the balloon 31 causes the capsule 30 to fall away.
  • the capsule is swallowed immediately after injection of the acid, and can be made of a material which gradually dissolves or is consumed in the stomach.
  • the balloon 40 is made of a material through which water may pass to a medium 41 within the balloon 40. which swells up on contact with the water.
  • a medium 41 is a cellulose material .
  • the balloon 40 is contained in a two-part capsule 42 which dissolves in the stomach or is consumed by it.

Abstract

An inflatable balloon (10) is placed in the stomach, to treat obesity by reducing appetite for food. The balloon can be inflated by liquid delivered to it by a supply line, (Fig. 1), by the gaseous reaction product of a chemical reaction within the ballon (Fig. 3) or by absorption of liquid through its semi-permeable wall (Fig. 4). The balloon is preferably piriform or ellipsoidal. Delivery to the stomach of the balloon (10) and supply line (13) by an overtube (14) with a closed smooth end presentation (16) is achieved by providing a fully-bounded side slit (17) in the overtube (14) from which the balloon (10) exists the overtube during its inflation. The balloon valve (11) and supply line (13) are preferably a mutual friction fit, enabling traction on the supply line alone to leave the balloon free-floating in the stomach following its inflation.

Description

ARTIFICIAL BEZOAR
BACKGROUND OF THE INVENTION
Field of the Invention
5 The present invention relates to artificial bezoars and to apparatus for treating obesity which includes an artificial bezoar.
10. Discussion of the Prior Art
There have been a number of proposals to treat obesity by use of an artificial bezoar. See, for example, GB-2139902-A, EP-0086862-A, W080/00007 and 83/02888 and
15 US4133315 and 4416267. One problem is to find a bezoar construction which retains its properties over an extended period of time while in residence in the stomach. Thus, an inflatable latex rubber balloon bezoar has been tried, but it was found that it tended to deflate over a relatively
20 short period. A second problem is how to achieve oral insertion without damaging oesophageal tissue, and yet another problem is to achieve reliable inflation of a balloon after it has been introduced into the stomach cavity.
25
EP-0137878-A discloses apparatus which includes a stomach tube which contains an uninflated stomach balloon at a leading end of the stomach tube. This one end of the stomach tube is slit to the end of the tube, and the slit
30 sides of the tube are laced together until the balloon is due to be inflated, when the lacing is removed. The arrangement is relatively complicated, and the slit and laced end of the stomach tube has a roughness of surface which makes it unattractive for oral introduction to the stomach.
It is one object of the present invention to provide ways of overcoming the above-mentioned difficulties.
SUMMARY OF THE INVENTION
10 According to a first aspect of the present invention there is provided apparatus for treating obesity in a patient, the apparatus comprising a valved balloon for placement in the stomach of the patient and a fluid supply line having a far end detachably connected to the valve and l& a near end for connection externally of the patient to a fluid supply means for inflation of the balloon within the stomach, the supply line and the balloon prior to its . inflation being accommodated within an overtube by which the balloon may be introduced orally into the stomach, the
20uninflated balloon being housed adjacent a leading end of the overtube, characterised in that the leading end of. the overtube is closed and has a smoothly convex shape, and in that the cylindrical wall of the overtube adjacent said closed leading end includes an elongate fully-bounded
25aperture which extends lengthwise of the overtube and through which the balloon exits the overtube in the course of its inflation.
It is convenient to use as the overtube a flexible tube 30of a length in a range from 60 to 70 cms and a diameter in the range of from 1 to 1.5 cms similar to the tubes which are currently employed for gastric aspiration. The tip of the overtube is smooth and the inflating balloon exits through a lengthwise sideways-facing slit-, so that the 35leading end of the overtube is easily introduced into the stomach and removed from it. Preferably, there is spacing, between the outside diameter of the fluid supply line and the inside diameter of the overtube, to allow for relative longitudinal movement of the supply line, as necessary, along the internal lumen of the overtube. At the proximal end of the supply line there may be a standard Luer fitting for convenient attachment to a fluid source, which may be, for example, a syringe or an infusion line. Conveniently, the leading i.e. distal end is tapered for insertion into a correspondingly shaped female element of the valve of the balloon for the purpose of inflation, and subsequent detachment by traction to leave the balloon free-floating in the stomach.
Construction of the balloon from acid-resistant material is essential. It has been found that latex and some other rubbers or plastics are rapidly destroyed by the acid and pepsin which are present in the gastric juice. Silicone rubber has, however, been found to be suitable.
Preferably, the balloon is of pear (piriform) or oval (ellipsoidal) shape and is of elastomeric material . Preferably, it is inflated through a self-sealing valve located at a narrow end of the balloon. A balloon of ellipsoidal or piriform shape complies more easily with the natural pear shape of the human stomach than does a spherical balloon, and without producing undue dilation of the central stomach. Such dilation could produce abdominal discomfort around the widest .parts of the balloon and impair the process of gastric emptying. In addition the longitudinal axis of the balloon will tend to align with the longitudinal axis of the stomach, and the balloon will be .Tiore likely to occupy space in the more proximal stomach where the satiety centre is thought to lie. A balloon of the preferred shape will furthermore leave less of the reservoir capacity of the stomach available for food storage and will have a greater flexibility for increased capacity without producing undue gastric distortion, stretching tension or mucosal damage.
The balloon should be adapted to contain about 500 millilitres of liquid under inflation in normal use, but preferably it should be able when required to accommodate liquid up to an amount of 1 litre or more. The wall thickness should be as small as .possible for passage along the oesophagus whilst deflated but large enough to withstand the long-term, potentially damaging, effects of intragastric acid, food products and pressure effects of the vigorously contracting stomach. Preferably, the chosen wall thickness is the optimum compromise between these opposed requi rements .
The balloon valve should be competent and continent against fluid leakage over a relatively long period of time, that is, a period of months, say six months. Preferably, it is constructed of the same material as the balloon for ease of manufacture and it should add to the weight of the balloon as little as possible.
According to a second aspect of the present invention there is provided an artificial bezoar being a capsule adapted to be swallowed or otherwise delivered orally to the stomach the capsule comprising a resilient balloon arranged in a compact, deflated disposition and containing a substance which is capable of undergoing a change of volume of at least two decimal orders of magnitude to inflate the balloon in the stomach.
One way in which the substance is capable of undergoing such a change of volume is for it to undergo a chemical reaction which results in the evolution of gas. Preferably, the gas should be one which does not harm the human body. Carbon dioxide is considered acceptable. For example, the capsule might contain a substance such as sodium bicarbonate which reacts with hydrochloric acid to generate gasesous carbon dioxide. The acid could be introduced into the capsule by injection with a needle through a self-sealing wall area of the capsule, and the capsule swallowed immediately thereafter so that inflation of the balloon takes place in the stomach. Tube delivery to the stomach, instead of swallowing, would avoid possible blockage of the oesophagus as a result of premature balloon inflation.
To achieve an inflated volume of 500 mis by chemical reaction between hydrochloric acid and sodium bicarbonate requires approximately 1 g of sodium bicarbonate and 1 'ml of N/10 hydrochloric acid.
An alternative possibility is to form the balloon from a material which is a semi -per eabl e membrane., and to enclose within the balloon a small amount of a substance which has the capacity to absorb, in large quantity, the water or gastric fluid which passes inwardly into the balloon through the semi -permeabl e membrane wall . It is thought that certain cellulose materials have the necessary properties. Conveniently, the balloon are packaged in a tight and compact disposition within a capsule which is adapted to be swallowed and is formed from a material which dissolves in the stomach to allow contact of the gastric fluids with the semi -permeabl e membrane balloon.
BRIEF DESCRIPTION OF THE DRAWINGS
In the accompanying drawings:
Figure 1 is a perspective view of a first embodiment of the invention;
Figure 2 is a scrap section along the longitudinal axis of the valve of the balloon of Figure 1;
Figure 3 is a side view, partly in .section, of a capsule which is a second embodiment of the invention; and
Figure 4 is view like Figure 3, of a third embodiment .
PREFERRED MODES FOR CARRYING OUT THE INVENTION
Referring to Figure 1 and 2, a balloon 10 of silicone rubber has a valve 11 which accommodates the distal end 12 of a liquid supply line 13 which extends the full length of an overtube 14 to a liquid supply syringe 15. For introduction of the balloon 10 to the stomach of a patient, it is packed in the overtube 14 adjacent its closed and smoothly rounded distal (leading) end 16. After the distal end 16 of the overtube 14 has been passed down the oesophagus to the stomach, liquid may be delivered down the supply line to the balloon 10 to inflate it and cause it to exit the overtube 14 through an elongate, fully bounded aperture 17 in the cylindrical wall of the overtube 14 adjacent its distal end 16.
Figure 2 shows the construction of the valve 11. A hollow stem 20 bonded to the wall of the balloon 10 has a closed end 21 but an aperture 22 in its cylindrical wall 23. A sealing sleeve 24 overlies the aperture 22 and allows liquid to flow from inside the stem 20 to inside the cavity of the balloon 10 but not in the opposite direction. In other embodiments, the sleeve 24 could be a skirt around the stem 20 or a flap over the aperture 22.
If manual deflation, of the balloon is required, the valve 11 can be so designed that manual squeezing of it will allow fluid to escape through the valve.
The distal end 12 of the supply line 13 is a firm friction fit in the stem 20. When the balloon has been inflated, tension on the supply line 13 will bring the balloon up against either the overtube or the oesophageal sphincter, and further pulling of the supply line will draw the distal end thereof out of the hollow stem 20 of the valve 11 and allow the balloon to float freely within the stomach, if the supply line is made of resilient material , tension on it will tend to reduce its diameter. This effect should assist its disengagement from the stem 20 of the valve 13.
The capsule 30 of Figure 3 contains a tightly-packed balloon 31 with a neck 32 bonded to an open end 33 of a short length of tube 34. The other end 35 of the tube 34 is closed by a self-sealing elasto eric plug 36 of a material which resists chemical attack by stomach acids but allows passage of a syringe needle and closes up after passage of the needle. Within the tube 34 is contained a quantity 37 of a substance which can undergo chemical reaction to generate gas to fill the balloon 31. For example, 500 ml of CO2 is generated by injecting 1 ml of N/10 Hydrochloric acid into 1 g of sodium bicarbonate. Inflation of the balloon 31 causes the capsule 30 to fall away. The capsule is swallowed immediately after injection of the acid, and can be made of a material which gradually dissolves or is consumed in the stomach.
In an alternative embodiment which avoids the risk of inflation in the oesophagus, illustrated in Figure 4, the balloon 40 is made of a material through which water may pass to a medium 41 within the balloon 40. which swells up on contact with the water. One such medium is a cellulose material . The balloon 40 is contained in a two-part capsule 42 which dissolves in the stomach or is consumed by it.

Claims

C L A I MS
1. Apparatus for treating obesity in a patient, the apparatus comprising a valved balloon (10) for placement in the stomach of the patient and a fluid supply line (13) having a far end (12) detachably connected to the valve (11) and a near end for connection externally of the patient to a fluid supply means (15) for inflation of the balloon within the stomach, the supply line and the balloon prior to its inflation being accommodated within an overtube (14) by which the balloon may be introduced orally into the stomach, the uninflated balloon being housed adjacent a leading end (16) of the overtube, characterised in that the leading end of the overtube is closed and has a smoothly convex shape, and in that the cylindrical wall of the overtube adjacent said closed leading end includes an elongate ful ly- bounded aperture 17 which extends lengthwise of the overtube and through which the balloon exists the overtube in the course of its inflation
2. Apparatus as claimed in claim 1 characterised in that the balloon is made of silicone rubber.
3. Apparatus as claimed in claim 1 characterised in that the balloon includes a self-sealing one-way inflation valve (11) with which the far end (12) of the supply line is a friction fit.
4. Apparatus as claimed in claim 3 characterised in that the valve (11 ) lies inside the envelope of the balloon and has1 a hollow stem (20) which extends from the skin of the balloon radially inwardly relative to the balloon skin, and the far end (12) of the supply line (13) extends into the hollow stem.
5. Apparatus as claimed in claim 4 characterised in that the valve includes a flexible valve member (24) which overlies a valve aperture (22) in the radially outer cylindrical surface (23) of the valve stem (20).
6. Apparatus for treating obesity comprising an artificial bezoar characterised in that it is constituted by a capsule (30) comprising a resilient balToon (31) arranged in a compact, deflated disposition and containing a substance (37) which is capable of undergoing a change of volume of at least two decimal orders of magnitude to inflate the balloon in the stomach.
7. Apparatus as claimed in claim 6 characterised in that said substance (37) is one which reacts with another substance to yield as reaction product a gas which serves to inflate the balloon (31 ).
8. Apparatus as claimed in claim 7 characterised in that said gas is carbon dioxide.
9. Apparatus as claimed in claim 7 characterised in that part (36) at least of the wall of the balloon permits injection into the balloon of said another substance for initiation of the gas yielding reaction, yet after such injection seals against efflux of gaseous reaction product from the injection site.
10. Apparatus as claimed in claim 6 characterised in that part at least of the wall surface of the balloon (40) is semi -permeabl e and in that the balloon contains a substance (41) which has the capacity to absorb in large quantity such water or gastric fluid which passes through said permeable wal 1.
11. Apparatus as claimed in claim 1 or 6, characterised in that the balloon is of piriform or ellipsoidal shape.
PCT/GB1986/000392 1985-07-05 1986-07-07 Artificial bezoar WO1987000034A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858517092A GB8517092D0 (en) 1985-07-05 1985-07-05 Artificial bezoar
GB8517092 1985-07-05

Publications (1)

Publication Number Publication Date
WO1987000034A2 true WO1987000034A2 (en) 1987-01-15

Family

ID=10581867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1986/000392 WO1987000034A2 (en) 1985-07-05 1986-07-07 Artificial bezoar

Country Status (3)

Country Link
EP (1) EP0232301A1 (en)
GB (1) GB8517092D0 (en)
WO (1) WO1987000034A2 (en)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000376A1 (en) * 1988-07-05 1990-01-25 Cantenys Jose Intragastric balloon
WO2000067682A1 (en) * 1999-05-06 2000-11-16 Lts Lohmann Therapie-Systeme Ag Gastric volume-reducing administration form
US6579301B1 (en) * 2000-11-17 2003-06-17 Syntheon, Llc Intragastric balloon device adapted to be repeatedly varied in volume without external assistance
WO2004084763A2 (en) 2003-03-19 2004-10-07 Phagia Technology Self-inflating intragastric volume-occupying device
WO2005107641A2 (en) 2004-05-03 2005-11-17 Fulfillium, Inc. Method and system for gastric volume control
WO2006055839A2 (en) 2004-11-19 2006-05-26 Fulfillium, Inc. Wireless breach detection
US7066945B2 (en) 2001-05-17 2006-06-27 Wilson-Cook Medical Inc. Intragastric device for treating obesity
WO2007113714A1 (en) * 2006-03-30 2007-10-11 Koninklijke Philips Electronics N.V. Expandable digestive pill
US7500944B2 (en) 2003-06-27 2009-03-10 Ethicon Endo-Surgery, Inc. Implantable band with attachment mechanism
WO2009128882A1 (en) * 2008-04-14 2009-10-22 Gore Enterprise Holdings, Inc. Intragastric volume-occupying device
US7951067B2 (en) 2003-06-27 2011-05-31 Ethicon Endo-Surgery, Inc. Implantable band having improved attachment mechanism
EP2356956A1 (en) 2006-03-28 2011-08-17 Spatz-Fgia Inc. Floating gastrointestinal anchor
WO2011136745A1 (en) * 2010-04-30 2011-11-03 Nanyang Technological University A balloon inflating device and a method for inflating a balloon
US8095218B2 (en) 2005-07-13 2012-01-10 Betastim, Ltd. GI and pancreatic device for treating obesity and diabetes
US8162969B2 (en) 2008-10-16 2012-04-24 Obalon Therapeutics, Inc. Intragastric device
US8216268B2 (en) * 2005-12-22 2012-07-10 Cook Medical Technologies Llc Intragastric bag for treating obesity
WO2012097225A2 (en) 2011-01-13 2012-07-19 Sensurtec, Inc. Breach detection in solid structures
WO2012099610A1 (en) 2011-01-21 2012-07-26 Obalon Therapeutics, Inc. Intragastric device
US8292911B2 (en) 2011-01-21 2012-10-23 Obalon Therapeutics, Inc. Intragastric device
US8403952B2 (en) 2004-12-27 2013-03-26 Spatz-Fgia, Inc. Floating gastrointestinal anchor
US8647358B2 (en) 2011-01-21 2014-02-11 Obalon Therapeutics Inc. Intragastric device
US8740927B2 (en) 2011-01-21 2014-06-03 Obalon Therapeutics Inc. Intragastric device
US8992561B2 (en) 2011-01-21 2015-03-31 Obalon Therapeutics, Inc. Intragastric device
US9155528B2 (en) 2012-01-08 2015-10-13 Vibrynt, Inc. Methods, instruments and devices for extragastic reduction of stomach volume
US9314362B2 (en) 2012-01-08 2016-04-19 Vibrynt, Inc. Methods, instruments and devices for extragastric reduction of stomach volume
US9456915B2 (en) 2004-11-19 2016-10-04 Fulfilium, Inc. Methods, devices, and systems for obesity treatment
US9895248B2 (en) 2014-10-09 2018-02-20 Obalon Therapeutics, Inc. Ultrasonic systems and methods for locating and/or characterizing intragastric devices
US9974680B2 (en) 2004-12-27 2018-05-22 Spatz Fgia, Inc. System and methods for internalization of external components of adjustable intragastric balloon
US10264995B2 (en) 2013-12-04 2019-04-23 Obalon Therapeutics, Inc. Systems and methods for locating and/or characterizing intragastric devices
US10335303B2 (en) 2015-12-07 2019-07-02 Obalon Therapeutics, Inc. Intragastric device
US10350100B2 (en) 2016-04-12 2019-07-16 Obalon Therapeutics, Inc. System for detecting an intragastric balloon
US10537453B2 (en) 2015-12-16 2020-01-21 Obalon Therapeutics, Inc. Intragastric device with expandable portions
US10857019B2 (en) 2012-11-26 2020-12-08 Spatz Fgia, Inc. System and methods for internalization of external components of an adjustable intragastric balloon
US10893966B2 (en) 2017-02-09 2021-01-19 Spatz FGIA Ltd Check valve with docking station for gastrointestinal balloon
US11819433B2 (en) 2016-11-04 2023-11-21 Reshape Lifesciences Inc. Pressure control system for intragastric device

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990000376A1 (en) * 1988-07-05 1990-01-25 Cantenys Jose Intragastric balloon
US5129915A (en) * 1988-07-05 1992-07-14 Jose Cantenys Intragastric balloon
WO2000067682A1 (en) * 1999-05-06 2000-11-16 Lts Lohmann Therapie-Systeme Ag Gastric volume-reducing administration form
US6579301B1 (en) * 2000-11-17 2003-06-17 Syntheon, Llc Intragastric balloon device adapted to be repeatedly varied in volume without external assistance
US7066945B2 (en) 2001-05-17 2006-06-27 Wilson-Cook Medical Inc. Intragastric device for treating obesity
EP1610737A2 (en) * 2003-03-19 2006-01-04 Phagia Technology Self-inflating intragastric volume-occupying device
EP2204149A3 (en) * 2003-03-19 2010-07-21 Obalon Therapeutics, Inc Self-inflating intragastric volume-occupying device
WO2004084763A2 (en) 2003-03-19 2004-10-07 Phagia Technology Self-inflating intragastric volume-occupying device
EP1610737A4 (en) * 2003-03-19 2008-04-02 Phagia Technology Self-inflating intragastric volume-occupying device
US7500944B2 (en) 2003-06-27 2009-03-10 Ethicon Endo-Surgery, Inc. Implantable band with attachment mechanism
US7951067B2 (en) 2003-06-27 2011-05-31 Ethicon Endo-Surgery, Inc. Implantable band having improved attachment mechanism
WO2005107641A2 (en) 2004-05-03 2005-11-17 Fulfillium, Inc. Method and system for gastric volume control
US8066780B2 (en) 2004-05-03 2011-11-29 Fulfillium, Inc. Methods for gastric volume control
WO2006055839A2 (en) 2004-11-19 2006-05-26 Fulfillium, Inc. Wireless breach detection
US9445930B2 (en) 2004-11-19 2016-09-20 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US9456915B2 (en) 2004-11-19 2016-10-04 Fulfilium, Inc. Methods, devices, and systems for obesity treatment
US11026825B2 (en) 2004-11-19 2021-06-08 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US9808367B2 (en) 2004-11-19 2017-11-07 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US8070807B2 (en) 2004-11-19 2011-12-06 Fulfillium, Inc. Wireless breach detection
US10179060B2 (en) 2004-11-19 2019-01-15 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US10524946B2 (en) 2004-11-19 2020-01-07 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US10285835B2 (en) 2004-11-19 2019-05-14 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US8403952B2 (en) 2004-12-27 2013-03-26 Spatz-Fgia, Inc. Floating gastrointestinal anchor
US9974680B2 (en) 2004-12-27 2018-05-22 Spatz Fgia, Inc. System and methods for internalization of external components of adjustable intragastric balloon
US8095218B2 (en) 2005-07-13 2012-01-10 Betastim, Ltd. GI and pancreatic device for treating obesity and diabetes
US8216268B2 (en) * 2005-12-22 2012-07-10 Cook Medical Technologies Llc Intragastric bag for treating obesity
AU2006330911B2 (en) * 2005-12-22 2012-10-04 Cook Medical Technologies Llc Intragastric bag for treating obesity
US8430894B2 (en) 2006-03-28 2013-04-30 Spatz-Fgia, Inc. Floating gastrointestinal anchor
EP2356956A1 (en) 2006-03-28 2011-08-17 Spatz-Fgia Inc. Floating gastrointestinal anchor
WO2007113714A1 (en) * 2006-03-30 2007-10-11 Koninklijke Philips Electronics N.V. Expandable digestive pill
WO2009128882A1 (en) * 2008-04-14 2009-10-22 Gore Enterprise Holdings, Inc. Intragastric volume-occupying device
US10327936B2 (en) 2008-10-16 2019-06-25 Obalon Therapeutics, Inc. Intragastric device
US8845674B2 (en) 2008-10-16 2014-09-30 Obalon Therapeutics, Inc. Intragastric device
US10085865B2 (en) 2008-10-16 2018-10-02 Obalon Therapeutics, Inc. Intragastric volume-occupying device and method for fabricating same
US11219543B2 (en) 2008-10-16 2022-01-11 Reshape Lifesciences Inc. Intragastric device
US9539132B2 (en) 2008-10-16 2017-01-10 Obalon Therapeutics, Inc. Intragastric device
US9072583B2 (en) 2008-10-16 2015-07-07 Obalon Therapeutics, Inc. Intragastric volume-occupying device and method for fabricating same
US10874537B2 (en) 2008-10-16 2020-12-29 Obalon Therapeutics, Inc. Intragastric volume-occupying device and method for fabricating same
US10675165B2 (en) 2008-10-16 2020-06-09 Obalon Therapeutics, Inc. Intragastric volume-occupying device and method for fabricating same
US8162969B2 (en) 2008-10-16 2012-04-24 Obalon Therapeutics, Inc. Intragastric device
WO2011136745A1 (en) * 2010-04-30 2011-11-03 Nanyang Technological University A balloon inflating device and a method for inflating a balloon
US9375554B2 (en) 2010-04-30 2016-06-28 National University Of Singapore Balloon inflating device and a method for inflating a balloon
WO2012097225A2 (en) 2011-01-13 2012-07-19 Sensurtec, Inc. Breach detection in solid structures
US8963708B2 (en) 2011-01-13 2015-02-24 Sensurtec, Inc. Breach detection in solid structures
US9504576B2 (en) 2011-01-13 2016-11-29 Sensurtec, Inc. Breach detection in solid structures
US8740927B2 (en) 2011-01-21 2014-06-03 Obalon Therapeutics Inc. Intragastric device
US10463520B2 (en) 2011-01-21 2019-11-05 Obalon Therapeutics, Inc. Intragastric device
US8647358B2 (en) 2011-01-21 2014-02-11 Obalon Therapeutics Inc. Intragastric device
US9827128B2 (en) 2011-01-21 2017-11-28 Obalon Therapeutics, Inc. Intragastric device
US11779482B2 (en) 2011-01-21 2023-10-10 Reshape Lifesciences Inc. Intragastric device
EP2665511A1 (en) * 2011-01-21 2013-11-27 Obalon Therapeutics, Inc. Intragastric device
US9468550B2 (en) 2011-01-21 2016-10-18 Obalon Therapeutics, Inc. Intragastric device
US8292911B2 (en) 2011-01-21 2012-10-23 Obalon Therapeutics, Inc. Intragastric device
US11737899B2 (en) 2011-01-21 2023-08-29 Reshape Lifesciences Inc. Intragastric device
WO2012099610A1 (en) 2011-01-21 2012-07-26 Obalon Therapeutics, Inc. Intragastric device
EP2665511A4 (en) * 2011-01-21 2014-06-11 Obalon Therapeutics Inc Intragastric device
US8992561B2 (en) 2011-01-21 2015-03-31 Obalon Therapeutics, Inc. Intragastric device
US9011477B2 (en) 2011-01-21 2015-04-21 Obalon Therapeutics, Inc. Intragastric device
US9662239B2 (en) 2011-01-21 2017-05-30 Obalon Therapeutics, Inc. Intragastric device
US9351862B2 (en) 2011-01-21 2016-05-31 Obalon Therapeutics, Inc. Intragastric device
US10773061B2 (en) 2011-01-21 2020-09-15 Obalon Therapeutics, Inc. Intragastric device
US10610396B2 (en) 2011-01-21 2020-04-07 Obalon Therapeutics, Inc. Intragastric device
US9314362B2 (en) 2012-01-08 2016-04-19 Vibrynt, Inc. Methods, instruments and devices for extragastric reduction of stomach volume
US9155528B2 (en) 2012-01-08 2015-10-13 Vibrynt, Inc. Methods, instruments and devices for extragastic reduction of stomach volume
US10857019B2 (en) 2012-11-26 2020-12-08 Spatz Fgia, Inc. System and methods for internalization of external components of an adjustable intragastric balloon
US10264995B2 (en) 2013-12-04 2019-04-23 Obalon Therapeutics, Inc. Systems and methods for locating and/or characterizing intragastric devices
US9895248B2 (en) 2014-10-09 2018-02-20 Obalon Therapeutics, Inc. Ultrasonic systems and methods for locating and/or characterizing intragastric devices
US10335303B2 (en) 2015-12-07 2019-07-02 Obalon Therapeutics, Inc. Intragastric device
US10537453B2 (en) 2015-12-16 2020-01-21 Obalon Therapeutics, Inc. Intragastric device with expandable portions
US10350100B2 (en) 2016-04-12 2019-07-16 Obalon Therapeutics, Inc. System for detecting an intragastric balloon
US11819433B2 (en) 2016-11-04 2023-11-21 Reshape Lifesciences Inc. Pressure control system for intragastric device
US10893966B2 (en) 2017-02-09 2021-01-19 Spatz FGIA Ltd Check valve with docking station for gastrointestinal balloon

Also Published As

Publication number Publication date
GB8517092D0 (en) 1985-08-14
EP0232301A1 (en) 1987-08-19

Similar Documents

Publication Publication Date Title
WO1987000034A2 (en) Artificial bezoar
EP1610737B1 (en) Self-inflating intragastric volume-occupying device
US4981471A (en) Device for intubation of percutaneous endoscopic ostomy
US4795430A (en) Device for intubation of percutaneous endoscopic ostomy
CN107913125B (en) Intragastric device
US20110178480A1 (en) Shunt Apparatus For Treating Obesity By Extracting Food
US20060058829A1 (en) Intragastric volume-occupying device
WO2009059803A1 (en) Externally inflatable gastric balloon device
WO2009059802A1 (en) Self-deflating gastric balloon device
GB2209121A (en) Balloon catheter inflation
CN103211568B (en) Auxiliary air bag sleeve for gastroscopy
US5100384A (en) Method and device for percutaneous intubation
CN207785324U (en) A kind of novel connection of intragastric balloon system and release structure
US4369789A (en) Inflatable gastric feeding tube
CN111420243A (en) Novel esophagus dilating balloon catheter
CN107126307B (en) Novel connection and release method and structure of intragastric balloon system
RU2455033C2 (en) Stomach volume change device
CN213048922U (en) Novel esophagus dilating balloon catheter
CN210019544U (en) Stomach tube for laparoscopic stomach slitting and removing operation
CN219517193U (en) Inflatable stomach tube and stomach tube assembly comprising same
CN212997505U (en) Stomach tube for assisting intestinal canal implantation
CN109224152A (en) Internally-fixed air bag drainage device
RU2609889C1 (en) Device for reduction of stomach volume
CN213608358U (en) Disposable feeding tube
CN213251371U (en) Stomach tube with end protector

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986904277

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986904277

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986904277

Country of ref document: EP